3rd Edition of Global Conference on
Pharmaceutics and Drug Delivery Systems
- June 24-26, 2019
- Paris, France
Dr. Mayssa studied pharmaceutical scinces at Misr International University in Cairo from which she graduated at 2007. She obtained her master’s degree from Ain Shams University in 2011 (Thesis topic “Vesicular formulations for controlled release olanzapine”). Dr. Mayssa obtained her PhD from Cairo University in 2017 (Thesis topic “Application of nanotechnology in ocular drug delivery”). She is holding position as researcher in National Research Center in Cairo since 2017. She has teaching experience in Fayoum, Nahda, MUST and Russian University in Egypt.
Many diseases that affect the eye have no symptoms like the glaucoma. Therefore, this disease has been called the “silent thief of sight” because it is characterized by gradual visual field loss over a long period of time and eventual blindness. Increase of the fluid pressure inside the eye (IOP) is the most important risk factor for glaucoma. Antiglaucoma agents may be administered topically or systemically for the treatment of elevated IOP. The most preferred method for treatment of ocular diseases is by topical application of drugs due to its ease of administration and low cost of production. Unavailingly, due to the very low ocular bioavailability for topically applied ocular formulations (less than 5%), the need of frequent application of doses is necessary. Because of multiple doses, poor patient compliance and damage to conjunctival and corneal cells may occur.
One of the most promising routes to target high concentrations of drugs into the eye is the periocular route as subconjunctival injection. Periocular drug administration refers to injection of the drug in the region surrounding the eye as the fibrous tissue of the sclera. Conjunctival instillation of thermosensitive mucoadhesive drug solutions may result in high drug concentration in the retina and vitreous. To treat ocular diseases using sustained release dosage forms, thermosensitive mucoadhesive sterosomal drug suspensions were developed.
Recently, it has been reviewed that mixture of single-chain amphiphiles and high content sterols can form fluid lamellar phases. Even though these single-chain amphiphiles or sterols do not form fluid lamellar phases once hydrated individually, their mixtures lead to stable liquid-ordered bilayers, and the resulting liposomes were named Sterosomes because of the high sterol content. Compared to the commercially available lipofectamine 2000, cationic Sterosomes formulated with stearylamine (SA) and cholesterol (Chol) showed significantly increased nanoparticle stability and cellular uptake efficiency.
Our present study focusses on the feasibility of use of sterosomes with different release modulations on the delivery of brinzolamide for the treatment of high IOP.
Audience take away:
• High IOP as a sight killer and ways to lower it.
• The audience will be able to know more about the recent advances in ocular drug delivery.
• The use of sterosomes in drug delivery